Why the study?
Does continuation of oral anticoagulation reduce thromboembolic events in patients after catheter ablation of atrial fibrillation?
Does continuation of oral anticoagulation reduce thromboembolic events in patients after catheter ablation of atrial fibrillation?
Continuing oral anticoagulation after atrial fibrillation ablation provides a net clinical benefit for patients with a CHA2DS2-VASc score ≥ 2, but offers no benefit for those with a score ≤ 1.
May support continuing OAC post-AF ablation only if CHA2DS2-VASc ≥2; leaves open need for RCTs to confirm net benefit.
Continuation of OAC after CA of AF with CHA₂ DS₂ VASc ≥ 2 is associated with a significant decreased TE risk and a favorable net clinical benefit in spite of ICH being significantly increased in the ON-OAC group. Continued OAC offers no benefit with CHA₂ DS₂ VASC ≤ 1.
No takes yet. Share an insight, caveat, or question.
Romero et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: